199 related articles for article (PubMed ID: 25071181)
21. Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.
Patel MR; Jay-Dixon J; Sadiq AA; Jacobson BA; Kratzke RA
J Thorac Oncol; 2013 Sep; 8(9):1142-7. PubMed ID: 23883783
[TBL] [Abstract][Full Text] [Related]
22. Role of Ras in metal-induced EGF receptor signaling and NF-kappaB activation in human airway epithelial cells.
Wu W; Jaspers I; Zhang W; Graves LM; Samet JM
Am J Physiol Lung Cell Mol Physiol; 2002 May; 282(5):L1040-8. PubMed ID: 11943669
[TBL] [Abstract][Full Text] [Related]
23. Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells.
Serizawa M; Murakami H; Watanabe M; Takahashi T; Yamamoto N; Koh Y
Cancer Sci; 2014 Jun; 105(6):683-9. PubMed ID: 24698130
[TBL] [Abstract][Full Text] [Related]
24. Mutation in Sos1 dominantly enhances a weak allele of the EGFR, demonstrating a requirement for Sos1 in EGFR signaling and development.
Wang DZ; Hammond VE; Abud HE; Bertoncello I; McAvoy JW; Bowtell DD
Genes Dev; 1997 Feb; 11(3):309-20. PubMed ID: 9030684
[TBL] [Abstract][Full Text] [Related]
25. Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer.
Milosevic N; Kühnemuth B; Mühlberg L; Ripka S; Griesmann H; Lölkes C; Buchholz M; Aust D; Pilarsky C; Krug S; Gress T; Michl P
Neoplasia; 2013 Dec; 15(12):1354-62. PubMed ID: 24403857
[TBL] [Abstract][Full Text] [Related]
26. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
Buck E; Eyzaguirre A; Brown E; Petti F; McCormack S; Haley JD; Iwata KK; Gibson NW; Griffin G
Mol Cancer Ther; 2006 Nov; 5(11):2676-84. PubMed ID: 17121914
[TBL] [Abstract][Full Text] [Related]
27. NF-κB activation is an early event of changes in gene regulation for acquiring drug resistance in human adenocarcinoma PC-9 cells.
Fukuoka M; Yoshioka K; Hohjoh H
PLoS One; 2018; 13(8):e0201796. PubMed ID: 30075033
[TBL] [Abstract][Full Text] [Related]
28. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.
Zhang X; Diaz MR; Yee D
Breast Cancer Res Treat; 2013 Jun; 139(2):351-60. PubMed ID: 23686416
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer.
Zheng L; Zhang Y; Mei S; Xie T; Zou Y; Wang Y; Jing H; Xu S; Dramou P; Xu Z; Li J; Zhou Y; Niu MM
J Med Chem; 2024 May; 67(9):7130-7145. PubMed ID: 38630077
[TBL] [Abstract][Full Text] [Related]
30. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.
Whitsett TG; Cheng E; Inge L; Asrani K; Jameson NM; Hostetter G; Weiss GJ; Kingsley CB; Loftus JC; Bremner R; Tran NL; Winkles JA
Am J Pathol; 2012 Jul; 181(1):111-20. PubMed ID: 22634180
[TBL] [Abstract][Full Text] [Related]
31. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.
Tabara K; Kanda R; Sonoda K; Kubo T; Murakami Y; Kawahara A; Azuma K; Abe H; Kage M; Yoshinaga A; Tahira T; Hayashi K; Arao T; Nishio K; Rosell R; Kuwano M; Ono M
PLoS One; 2012; 7(7):e41017. PubMed ID: 22815900
[TBL] [Abstract][Full Text] [Related]
32. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
Park KS; Raffeld M; Moon YW; Xi L; Bianco C; Pham T; Lee LC; Mitsudomi T; Yatabe Y; Okamoto I; Subramaniam D; Mok T; Rosell R; Luo J; Salomon DS; Wang Y; Giaccone G
J Clin Invest; 2014 Jul; 124(7):3003-15. PubMed ID: 24911146
[TBL] [Abstract][Full Text] [Related]
33. Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells.
Thelemann A; Petti F; Griffin G; Iwata K; Hunt T; Settinari T; Fenyo D; Gibson N; Haley JD
Mol Cell Proteomics; 2005 Apr; 4(4):356-76. PubMed ID: 15657067
[TBL] [Abstract][Full Text] [Related]
34. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
35. Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.
Fong JT; Jacobs RJ; Moravec DN; Uppada SB; Botting GM; Nlend M; Puri N
PLoS One; 2013; 8(11):e78398. PubMed ID: 24223799
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy.
Ali S; El-Rayes BF; Sarkar FH; Philip PA
Mol Cancer Ther; 2005 Dec; 4(12):1943-51. PubMed ID: 16373709
[TBL] [Abstract][Full Text] [Related]
37. Type II cGMP-dependent protein kinase inhibits EGF-induced MAPK/JNK signal transduction in breast cancer cells.
Lan T; Chen Y; Sang J; Wu Y; Wang Y; Jiang L; Tao Y
Oncol Rep; 2012 Jun; 27(6):2039-44. PubMed ID: 22427012
[TBL] [Abstract][Full Text] [Related]
38. Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.
Zhang X; Belkina N; Jacob HK; Maity T; Biswas R; Venugopalan A; Shaw PG; Kim MS; Chaerkady R; Pandey A; Guha U
Proteomics; 2015 Jan; 15(2-3):340-55. PubMed ID: 25404012
[TBL] [Abstract][Full Text] [Related]
39. Sos1 rapidly associates with Grb2 and is hypophosphorylated when complexed with the EGF receptor after EGF stimulation.
Hu Y; Bowtell DD
Oncogene; 1996 May; 12(9):1865-72. PubMed ID: 8649846
[TBL] [Abstract][Full Text] [Related]
40. Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival.
Lypova N; Telang S; Chesney J; Imbert-Fernandez Y
J Biol Chem; 2019 Jul; 294(27):10530-10543. PubMed ID: 31126985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
